Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.

Phase 1TerminatedNCT00195325

Wyeth is now a wholly owned subsidiary of Pfizer45 enrolled

Overview

The purpose of this study is to evaluate the safety, tolerability, and MTD (maximum tolerated dose) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

ECT

Masking

NONE

Enrollment

Conditions

Tumors Neoplasms

Interventions

TTI-237DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Documented diagnosis of malignant solid tumor with measurable disease * Life expectancy of at least 12 weeks * ECOG (The Eastern Cooperative Oncology Group scale) performance status of 0, 1, or 2 Exclusion Criteria: * Recent major surgery, radiation therapy or anti-cancer treatment * History of any other prior malignancy within the last 5 years

Locations (3)

Unnamed facility

Lexington, Kentucky, United States

Unnamed facility

Cleveland, Ohio, United States

Unnamed facility

Nashville, Tennessee, United States

Outcomes

Primary Outcomes

To determine safety, tolerability, and MTD of TTI-237 - patients are monitored during the duration of their participation on the trial.

Secondary Outcomes

Preliminary pharmacokinetics (during cycle 1) and anti-tumor activity of TTI-237 (approximately every 8 weeks).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.